A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
A phase 3 trial testing D-0502 in HR-positive / HER2-negative breast cancer, now recruiting.
Overview
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT06954961, led by InventisBio, and recruiting when checked on 2026-09-11. Official title: A Randomised, Parallel-controlled, Open-label, Multicenter Phase III Clinical Study to Compare the Efficacy and Safety of D-0502 With Fulvestrant in Patients With Previously Treated ER-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer. Planned enrolment is 640 participants (estimated). The study started in 2022-09-15 and primary completion is expected in 2026-11-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialStudy of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialPhase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialPhase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialSafety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.